Estrella Immunopharma, Inc. (ESLAW) stock
Close on Nov 13, 2026Market cap $22.36MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $22.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.31M
- EPS, diluted
- -$0.27
- Book value per share
- -$0.17
- Diluted shares
- 43M
Trading
- Previous close
- $0.07
- Open
- $0.09
- Day's range
- $0.09 – $0.09
- Volume
- 1,000
- Average volume (20 days)
- 8,884
- Beta (5 years)
- 0.97
- 52-week range
- $0.24 – $2.43
- RSI (14 days)
- 47.6
- Volatility (1 year)
- 157.9%
- Relative volume
- 0.16×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ESLAW | S&P 500 | Difference | ESLAW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +66.9% | -3.0% | +70.0 pts | ||
| 3 months | +25.8% | -2.8% | +28.6 pts | ||
| Year to date | +75.6% | +11.5% | +64.1 pts | ||
| 1 year | -27.0% | +13.5% | −40.4 pts | ||
| 3 years | +101.4% | +77.7% | +23.7 pts | +26.3% | +21.1% |
| 5 years | -83.1% | +72.6% | −155.7 pts | -29.9% | +11.5% |
Three years at a glance
Fiscal years 2020 to 2024, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Estrella Immunopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- News
About Estrella Immunopharma
Biological Products, (No Diagnostic Substances)
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company that develops engineered T-cell therapies for individuals with hematologic cancers, solid tumors, and autoimmune diseases. Its therapeutic programs utilize a proprietary receptor platform designed to regulate T-cell activation. The company's lead product candidate, EB103, targets CD19 and is under clinical evaluation for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, particularly those ineligible for existing treatments. Additionally, the company develops EB104, a dual-targeting therapy directed against CD19 and CD22 for blood cancers, and EB201, a preclinical program targeting systemic lupus erythematosus. Its primary end users are patients suffering from severe malignancies and immune disorders.
Company profile, executives and historyEstrella Immunopharma stock: common questions
What is Estrella Immunopharma's stock price?
ESLAW closed at $0.09 on Nov 13, 2026, up 25.07% on the day. Over the past 52 weeks it traded between $0.24 and $2.43.
What is Estrella Immunopharma's market cap?
Estrella Immunopharma was worth $22.36M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ESLAW's P/E ratio?
Estrella Immunopharma lost money over the twelve months to Jun 30, 2024 (diluted EPS -$0.27), so it has no meaningful P/E ratio.
Does Estrella Immunopharma pay a dividend?
No. Estrella Immunopharma has not paid a cash dividend over the last twelve months.
How has ESLAW stock performed over the past year?
Including dividends, ESLAW returned -27.0% over the past year, against +13.5% for the S&P 500.
Who are Estrella Immunopharma's competitors?
Companies most similar to Estrella Immunopharma by business, industry and size include INAB, TCRX, ATRA, CABA, CRBU.
See a number that looks wrong?